Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patients, between the ages of 18 and 65
Patients must have diagnosis of schizophrenia that meets disease diagnostic criteria as defined in DSM-IV
Patients must be considered, by the investigator, to be clinically agitated and appropriate candidates for treatment with IM medication. Investigator must believe that it is safe to administer IM olanzapine and IM comparator to the patients with respect to the safety profile of these drugs (including the anticholinergic properties of Olanzapine IM or the comparator agent)
Subjects' illness must not, in the opinion of the investigator, be caused by substance abuse
Patient must be hospitalized during the study
You may not be if
Previous participation (treatment with study drug) in a Lilly sponsored intra-muscular olanzapine clinical trial
Serious, unstable illnesses such that death is anticipated within 1 year or intensive care unit hospitalization for the disease is anticipated within 6 months
Have a known diagnosis of dementia of any type, as defined in the DSM-IV or DSM-IV-TR
Documented history of allergic reaction to study medication(s)
Treatment with an injectable depot neuroleptic within 1 injection interval prior to study drug administration
Clareo Health | Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia
